318 related articles for article (PubMed ID: 28885700)
1. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.
London WB; Bagatell R; Weigel BJ; Fox E; Guo D; Van Ryn C; Naranjo A; Park JR
Cancer; 2017 Dec; 123(24):4914-4923. PubMed ID: 28885700
[TBL] [Abstract][Full Text] [Related]
2. Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma.
Villablanca JG; Ji L; Shapira-Lewinson A; Marachelian A; Shimada H; Hawkins RA; Pampaloni M; Lai H; Goodarzian F; Sposto R; Park JR; Matthay KK
Pediatr Blood Cancer; 2018 May; 65(5):e26940. PubMed ID: 29350464
[TBL] [Abstract][Full Text] [Related]
3. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
4. Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621).
Fox E; Mosse' YP; Meany HM; Gurney JG; Khanna G; Jackson HA; Gordon G; Shusterman S; Park JR; Cohn SL; Adamson PC; London WB; Maris JM; Balis FM
Pediatr Blood Cancer; 2014 Jun; 61(6):990-6. PubMed ID: 24347462
[TBL] [Abstract][Full Text] [Related]
5. Treatment with topotecan plus cyclophosphamide in children with first relapse of neuroblastoma.
Ashraf K; Shaikh F; Gibson P; Baruchel S; Irwin MS
Pediatr Blood Cancer; 2013 Oct; 60(10):1636-41. PubMed ID: 23650219
[TBL] [Abstract][Full Text] [Related]
6. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Yalçin B; Kremer LC; van Dalen EC
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD006301. PubMed ID: 26436598
[TBL] [Abstract][Full Text] [Related]
7. Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials.
Moreno L; Rubie H; Varo A; Le Deley MC; Amoroso L; Chevance A; Garaventa A; Gambart M; Bautista F; Valteau-Couanet D; Geoerger B; Vassal G; Paoletti X; Pearson AD
Pediatr Blood Cancer; 2017 Jan; 64(1):25-31. PubMed ID: 27555472
[TBL] [Abstract][Full Text] [Related]
8. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Yalçin B; Kremer LC; Caron HN; van Dalen EC
Cochrane Database Syst Rev; 2013 Aug; (8):CD006301. PubMed ID: 23970444
[TBL] [Abstract][Full Text] [Related]
9. Predictors of survival in patients with high-risk neuroblastoma who failed tandem high-dose chemotherapy and autologous stem cell transplantation.
Yi ES; Son MH; Hyun JK; Cho HW; Ju HY; Lee JW; Yoo KH; Sung KW; Koo HH
Pediatr Blood Cancer; 2020 Feb; 67(2):e28066. PubMed ID: 31736249
[TBL] [Abstract][Full Text] [Related]
10. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641.
Strother DR; London WB; Schmidt ML; Brodeur GM; Shimada H; Thorner P; Collins MH; Tagge E; Adkins S; Reynolds CP; Murray K; Lavey RS; Matthay KK; Castleberry R; Maris JM; Cohn SL
J Clin Oncol; 2012 May; 30(15):1842-8. PubMed ID: 22529259
[TBL] [Abstract][Full Text] [Related]
11. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.
Kushner BH; Ostrovnaya I; Cheung IY; Kuk D; Modak S; Kramer K; Roberts SS; Basu EM; Yataghene K; Cheung NK
Oncotarget; 2016 Jan; 7(4):4155-66. PubMed ID: 26623730
[TBL] [Abstract][Full Text] [Related]
12. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study.
London WB; Frantz CN; Campbell LA; Seeger RC; Brumback BA; Cohn SL; Matthay KK; Castleberry RP; Diller L
J Clin Oncol; 2010 Aug; 28(24):3808-15. PubMed ID: 20660830
[TBL] [Abstract][Full Text] [Related]
13. A new risk score for patients after first recurrence of stage 4 neuroblastoma aged ≥18 months at first diagnosis.
Kreitz K; Ernst A; Schmidt R; Simon T; Fischer M; Volland R; Hero B; Berthold F
Cancer Med; 2019 Dec; 8(17):7236-7243. PubMed ID: 31631570
[TBL] [Abstract][Full Text] [Related]
14. Systematic review of phase-I/II trials enrolling refractory and recurrent Ewing sarcoma: Actual knowledge and future directions to optimize the research.
Felix A; Berlanga P; Toulmonde M; Landman-Parker J; Dumont S; Vassal G; Le Deley MC; Gaspar N
Cancer Med; 2021 Mar; 10(5):1589-1604. PubMed ID: 33452711
[TBL] [Abstract][Full Text] [Related]
15. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
[TBL] [Abstract][Full Text] [Related]
16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
17. Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531.
Twist CJ; Schmidt ML; Naranjo A; London WB; Tenney SC; Marachelian A; Shimada H; Collins MH; Esiashvili N; Adkins ES; Mattei P; Handler M; Katzenstein H; Attiyeh E; Hogarty MD; Gastier-Foster J; Wagner E; Matthay KK; Park JR; Maris JM; Cohn SL
J Clin Oncol; 2019 Dec; 37(34):3243-3255. PubMed ID: 31386611
[TBL] [Abstract][Full Text] [Related]
18. Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma.
Cheung NK; Cheung IY; Kramer K; Modak S; Kuk D; Pandit-Taskar N; Chamberlain E; Ostrovnaya I; Kushner BH
Int J Cancer; 2014 Nov; 135(9):2199-205. PubMed ID: 24644014
[TBL] [Abstract][Full Text] [Related]
19. A nationwide phase II study of delayed local treatment for children with high-risk neuroblastoma: The Japan Children's Cancer Group Neuroblastoma Committee Trial JN-H-11.
Yoneda A; Shichino H; Hishiki T; Matsumoto K; Ohira M; Kamijo T; Kuroda T; Soejima T; Nakazawa A; Takimoto T; Yokota I; Teramukai S; Takahashi H; Fukushima T; Hara J; Kaneko M; Ikeda H; Tajiri T; Mugishima H; Nakagawara A
Pediatr Blood Cancer; 2024 Jun; 71(6):e30976. PubMed ID: 38577760
[TBL] [Abstract][Full Text] [Related]
20. Salvage rates after progression of high-risk neuroblastoma with a soft tissue mass.
Murphy JM; Lim II; Farber BA; Heaton TE; Basu EM; Roberts SS; Modak S; Kushner BH; LaQuaglia MP
J Pediatr Surg; 2016 Feb; 51(2):285-8. PubMed ID: 26651282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]